Clinical trials with retinoids for breast cancer chemoprevention
Open Access
- 1 March 2006
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 13 (1) , 51-68
Abstract
Retinoids have been studied as chemopreventive agents in clinical trials due to their established role in regulating cell growth, differentiation and apoptosis in preclinical models. Experimental evidence suggests that retinoids affect gene expression both directly, by activating and/or repressing specific genes, and indirectly, by interfering with different signal transduction pathways. Induction of apoptosis is a unique feature of fenretinide, the most widely studied retinoid in clinical trials on breast cancer chemoprevention due to its selective accumulation in breast tissue and to its favourable toxicological profile. In a phase III breast cancer prevention trial, fenretinide showed a durable trend to a reduction of second breast malignancies in premenopausal women. This pattern was associated with a favourable modulation of circulating IGF-I and its main binding protein (IGF-binding protein-3, IGFBP-3), which have been associated with breast cancer risk in premenopausal women in different prospective studies. In a subsequent biomarker study on premenopausal women who had participated in the phase III trial, high IGF-I and low IGFBP-3 baseline levels were found to predict second breast cancer risk, although the magnitude of their changes during treatment did not fulfil the requirements for suitable surrogate end-point biomarkers. In postmenopausal women, fenretinide did not reduce second breast cancer incidence, nor did it induce significant modulation of the IGF system. Similarly, fenretinide was not found to affect risk biomarkers significantly in early postmenopausal women on hormone replacement therapy, who are at increased risk of developing breast cancer. Biomarker studies of fenretinide alone or in combination with different nuclear receptor ligands are being conducted. In particular, clinical trials of fenretinide and tamoxifen have proved to be feasible, and this combination appears to be safe and well tolerated in high-risk women, especially when low-dose tamoxifen is employed. Novel retinoid X receptor-selective retinoids, or rexinoids, have been shown to suppress the development of breast cancer in several animal models with minimal toxicity, and are being intensively studied either alone or in combination with selective oestrogen receptor modulators, both in vitro and in vivo. The rexinoid, bexarotene, has recently been approved for the treatment of patients with cutaneous T-cell lymphoma, and a biomarker trial with bexarotene in women with high breast cancer risk is currently underway.Keywords
This publication has 95 references indexed in Scilit:
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004
- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism riskThe Lancet, 2003
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Serum insulin-like growth factor-I and breast cancerInternational Journal of Cancer, 2000
- Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of actionvia regulation of retinoid receptors expressionInternational Journal of Cancer, 1998
- Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patientsInternational Journal of Cancer, 1998
- Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eyeEuropean Journal of Cancer, 1996
- Retinoid receptors in human lung cancer and breast cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996
- In vitro interaction of fenretinide with plasma retinol‐binding protein and its functional consequencesFEBS Letters, 1992
- RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors.The EMBO Journal, 1992